A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State

A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State

Fexuprazan is a potassium-competitive acid blocker approved for treating gastric-acid-related diseases. Although the effectiveness of the recent formulation fexuprazan 10 mg has been demonstrated in Phase 3 clinical trials, data on the pharmacokinetics (PKs) of administering fexuprazan 10 mg twice d...

Full description

Bibliographic Details
Main Authors: Wonsuk Shin, A-Young Yang, Hyung Park, Hyejung Lee, Hyounggyoon Yoo, Anhye Kim
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:Pharmaceuticals
Subjects:
pharmacokinetics
bioequivalence
gastritis
multiple dose
fexuprazan
Online Access:https://www.mdpi.com/1424-8247/16/8/1141

Similar Items

Similar Items